SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-22-026636
Filing Date
2022-12-16
Accepted
2022-12-16 08:31:07
Documents
12
Period of Report
2022-12-13
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 8-K labp-20221213.htm   iXBRL 8-K 50329
  Complete submission text file 0000950170-22-026636.txt   166517

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT labp-20221213.xsd EX-101.SCH 2478
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT labp-20221213_lab.xml EX-101.LAB 13350
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT labp-20221213_pre.xml EX-101.PRE 9846
6 EXTRACTED XBRL INSTANCE DOCUMENT labp-20221213_htm.xml XML 4696
Mailing Address 1800 KRAFT DRIVE, SUITE 216 BLACKSBURG VA 24060
Business Address 1800 KRAFT DRIVE, SUITE 216 BLACKSBURG VA 24060 540-818-2844
Landos Biopharma, Inc. (Filer) CIK: 0001785345 (see all company filings)

IRS No.: 815085535 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39971 | Film No.: 221466541
SIC: 2834 Pharmaceutical Preparations